Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 11

  • 1 389 clinical trials
  • 585 recruiting
  • 453 conditions
  • 29 countries

Conditions in this area

453 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis43Glioblastoma40Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Cognitive disorder18Epilepsy18Giant cell arteritis18Partial seizures18Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Anaesthesia16Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+429

Clinical trials in Nervous system disorders

1 389 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 389 clinical trials

Multiple system atrophy

Recruiting

A Study of Emrusolmin Safety and Effectiveness in Adults with Multiple System Atrophy, a Brain and Nerve Disorder

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Emrusolmin
  • Sponsor:Teva Branded Pharmaceutical Products R&D LLC

Multiple sclerosis

Recruiting

A study of RO7268489 added to ocrelizumab compared to placebo in adults with progressive multiple sclerosis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Spinal cord injury

Recruiting

A study testing Wharton's jelly-derived mesenchymal stem cells with spinal cord stimulation for adults with chronic spinal cord injury

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:ALLOGENEIC VIABLE WHARTON'S JELLY-DERIVED MESENCHYMAL STEM CELLS, EX-VIVO EXPANDED
  • Sponsor:Fundacio Institut Guttmann

Parkinson's disease

Recruiting

A Study Testing if Daily Tadalafil Improves Movement Symptoms in Patients with Early-Stage Parkinson's Disease Who Have Not Yet Started Treatment

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Tadalafil
  • Sponsor:Amsterdam UMC Stichting

Ischaemic stroke

Recruiting

A Study of Tenecteplase for Acute Ischemic Stroke in Patients Taking Direct Oral Anticoagulants

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tenecteplase
  • Sponsor:University Medical Center Hamburg-Eppendorf

Seizure

Recruiting

Study of Pyridoxal Phosphate for Treatment of Seizures in Patients with PNPO Deficiency

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Medicure International Inc.

Neurofibromatosis+1

Recruiting

A study of mirdametinib for infants and toddlers under 24 months of age with neurofibromatosis type 1 associated plexiform neurofibromas

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Sponsor:Merck Healthcare KGaA

Trisomy 21

Recruiting

Study of AEF0217 compared to placebo for improving behavior and thinking skills in adults and older adolescents with Down syndrome

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:1-((3S,8S,9S,10R,13S,14S,17S)3-BENZYLOXY-10,13,17-TRIMETHYL-2,3,4,7,8,9,10,11,12,13,14,15,16,17-TETRADECAHYDRO-1HCYCLOPENTA[A]PHENANTHRENE-17-YL)ETHAN-1-ONE
  • Sponsor:Aelis Farma

Leukodystrophy

Recruiting

A study of guanabenz acetate for children with vanishing white matter disease who started treatment in early childhood

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:Guanabenz Acetate
  • Sponsor:Amsterdam UMC Stichting

Post lumbar puncture syndrome

Recruiting

Comparing Sphenopalatine Block Using Lidocaine and Prilocaine to Blood Patch for Patients with Post-Dural Puncture Syndrome

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lidocaine
  • Sponsor:University Hospital Of Clermont-Ferrand

Astrocytoma

Recruiting

Testing Tuvusertib in Patients with Returning IDH and ATRX Mutant Astrocytoma Brain Tumor

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Tuvusertib
  • Sponsor:Grupo Espanol De Investigacion En Neurooncologia

Narcolepsy

Recruiting

A Study to Test the Safety and Effectiveness of TAK-360 in People with Narcolepsy without Cataplexy

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Takeda Development Center Americas Inc.

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride72 clinical trialsTemozolomide37 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide25 clinical trialsParacetamol24 clinical trialsCarboplatin15 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.